A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News HighlightsAerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated ... Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial R... Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval ...
May 22, 4:00 PM ET
52 - WEEK LOW/HIGH